Development
Thermo Fisher Scientific Inc.
TMO
$408.53
$6.631.65%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 10.89B | 10.57B | 10.69B | 10.71B | 11.45B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.89B | 10.57B | 10.69B | 10.71B | 11.45B |
| Cost of Revenue | 6.49B | 6.25B | 6.43B | 6.54B | 6.84B |
| Gross Profit | 4.40B | 4.32B | 4.26B | 4.17B | 4.61B |
| SG&A Expenses | 2.04B | 2.05B | 2.15B | 2.11B | 2.18B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.00M | -- | -- | -- | -- |
| Total Operating Expenses | 8.86B | 8.63B | 8.92B | 9.00B | 9.41B |
| Operating Income | 2.03B | 1.95B | 1.76B | 1.71B | 2.04B |
| Income Before Tax | 1.74B | 1.75B | 1.41B | 1.34B | 1.75B |
| Income Tax Expenses | 133.00M | 53.00M | 52.00M | 46.00M | 173.00M |
| Earnings from Continuing Operations | 1.61B | 1.70B | 1.36B | 1.29B | 1.57B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 24.00M | 20.00M | -1.00M | -3.00M | 2.00M |
| Net Income | 1.63B | 1.72B | 1.36B | 1.29B | 1.58B |
| EBIT | 2.03B | 1.95B | 1.76B | 1.71B | 2.04B |
| EBITDA | 2.87B | 2.80B | 2.62B | 2.57B | 2.88B |
| EPS Basic | 4.21 | 4.44 | 3.53 | 3.34 | 4.03 |
| Normalized Basic EPS | 3.17 | 3.00 | 2.59 | 2.47 | 3.09 |
| EPS Diluted | 4.20 | 4.42 | 3.51 | 3.32 | 3.99 |
| Normalized Diluted EPS | 3.16 | 2.99 | 2.57 | 2.46 | 3.08 |
| Average Basic Shares Outstanding | 387.00M | 386.00M | 386.00M | 386.00M | 391.00M |
| Average Diluted Shares Outstanding | 388.00M | 388.00M | 388.00M | 388.00M | 393.00M |
| Dividend Per Share | 0.35 | 0.35 | 0.35 | 0.35 | 0.30 |
| Payout Ratio | 8.34% | 7.87% | 9.92% | 9.08% | 7.42% |